drugset / Trial / NCT07202546
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.
Timeline
- Start
- 2026-02-11
- Primary completion
- 2027-07-26
- Completion
- 2028-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dolutegravir | Other / unclassified | — | Oral |
| Comparator | Lamivudine | Other / unclassified | — | Oral |
| Subject | VH4524184 | Unknown | — | Oral |
| Background | emtricitabine | Other / unclassified | — | Oral |
| Background | tenofovir alafenamide | Small molecule | — | Oral |